Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 3cMET-dysregulated Advanced Solid Tumors 2Neoplasm Metastasis 2Glioblastoma 2Colorectal Neoplasms 2cMET Dysegulation Advanced Solid Tumors 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Neoplasms 1Lung Neoplasms 1Laryngeal Diseases 1Hepatic Impairment 1Gliosarcoma 1EGFR-mutant Non-small Cell Lung Cancer 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Advanced Solid Tumor 1

Interventions

Cisplatin 3Radiotherapy 2Cetuximab 2pembrolizumab 1capmatinib 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Radiation 1N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 1MLN 8237 1Drug Therapy 1Alkylating Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Laryngeal Diseases × capmatinib × Clear all
NCT02205398 2019-01-22

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Novartis

Phase 1 Terminated
13 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡